Drug intelligence / Profile preview

darolutamide + goserelin + pertuzumab + trastuzumab

Development stage: Unknown
Lead developer: Peking Union Medical College
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

This combination regimen consists of the non-steroidal androgen receptor (AR) antagonist darolutamide, the gonadotropin-releasing hormone (GnRH) agonist goserelin, and the human epidermal growth factor receptor 2 (HER2)-targeted monoclonal antibodies pertuzumab and trastuzumab. It is being evaluated in a Phase 2 umbrella trial (NCT05933408) led by Peking Union Medical College for the treatment of salivary gland carcinoma (SGC). The regimen is specifically designed for patients whose tumors exhibit dual expression of AR and HER2, a molecular profile often found in salivary duct carcinoma. By simultaneously inhibiting the AR signaling pathway (via darolutamide and goserelin) and the HER2 pathway (via pertuzumab and trastuzumab), the therapy aims to overcome potential resistance mechanisms and improve clinical outcomes in this biomarker-selected population.

Other names: darolutamide + goserelin + pertuzumab + trastuzumab-Peking Union Medical College-salivary gland carcinoma

Targets

GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on darolutamide + goserelin + pertuzumab + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on darolutamide + goserelin + pertuzumab + trastuzumab.

Explore the full profile